2024-09-02 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a diverse range of products, including medical devices, pharmaceuticals, diagnostics, and nutritionals. 

**Performance Analysis:**

**1.  Return Rate Comparison:**

* **ABT's cumulative return:** 41.96%
* **S&P 500 (VOO) cumulative return:** 89.66%
* **Return gap:** -47.7% (relative divergence: 14.85%)
* **Interpretation:** ABT has underperformed the S&P 500 by 47.7% over the period analyzed. This places its performance in the 14.85th percentile compared to its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* **Closing price:** 113.27
* **5-day moving average:** 112.95
* **20-day moving average:** 110.9
* **60-day moving average:** 106.71
* **Interpretation:** ABT's recent price movement suggests a short-term uptrend, as the current price is above all moving averages.  The 5-day moving average being slightly above the closing price indicates potential for a slight correction.

**3. Technical Indicators:**

* **RSI:** 82.52
* **PPO:** 0.03
* **Delta Previous Relative Divergence:** -8.38 (short-term downtrend)
* **Expected Return:** 27.09% (5-year estimated return)
* **Interpretation:** ABT's RSI is in overbought territory, suggesting potential for a near-term correction. The PPO indicates a positive momentum, but the negative delta in relative divergence suggests a potential short-term downtrend. The high expected return reflects the potential for long-term growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

* **Interpretation:** Abbott Laboratories has shown consistent revenue growth, with a slight decrease in EPS in recent quarters. The latest earnings report for Q2 2024 showed that ABT beat earnings estimates by 1 cent, with EPS coming in at $0.74 compared to an expected $0.73. Revenue also exceeded expectations, reaching $10.38 billion against an expected $10.35 billion.

**5.  Overall Analysis:**

Abbott Laboratories' recent performance has been mixed. While the stock has underperformed the S&P 500 over the period analyzed, recent earnings have shown positive growth. The stock is currently overbought according to RSI, suggesting potential for a short-term correction, but the positive PPO and high expected return highlight the potential for long-term growth. The overall direction of the stock is uncertain, but the company's consistent earnings growth and strong market position suggest a favorable long-term outlook. 
